Annual report pursuant to Section 13 and 15(d)

Income Taxes

v3.8.0.1
Income Taxes
12 Months Ended
Dec. 31, 2017
Income Tax Disclosure [Abstract]  
Income Taxes

(7) Income Taxes

 

Tax positions must meet a “more likely than not” recognition threshold at the effective date to be recognized. At December 31, 2017 and 2016, the Company did not have any uncertain tax positions. No interest and penalties related to uncertain tax positions were accrued at December 31, 2017 and 2016. Our tax returns for fiscal years 2014, 2015 and 2016 are open to examination.

 

We did not record an income tax benefit or provision for the years ended December 31, 2017 and 2016.

 

Significant items making up the deferred tax assets and deferred tax liabilities as of December 31, 2017 and 2016 are as follows:

 

    2017     2016  
Long term deferred taxes:                
Inventories   $ 49,067     $ 7,856  
Accounts receivable allowance     -       17,253  
Other accruals     75,992       33,399  
Accelerated tax depreciation     6,945       14,582  
Non-cash, stock-based compensation, nonqualified     606,020       711,676  
Impairment loss on investment     103,748       146,782  
Goodwill and intangibles     -       -  
Operating loss carry forwards and tax credits     12,196,765       13,561,012  
Less: valuation allowance     (13,038,537      (14,492,560 )
Total net deferred tax assets   $ -     $ -  

 

A valuation allowance is established if it is more likely than not that all or a portion of the deferred tax asset will not be realized. Accordingly, a valuation allowance was established in 2017 and 2016 for the full amount of our deferred tax assets due to the uncertainty of realization. We believe based on our projection of future taxable operating income for the foreseeable future, it is more likely than not that we will not be able to realize the benefit of the deferred tax asset at December 31, 2017.

 

On December 22, 2017, the U.S. Tax Cuts and Jobs Act (the "Tax Reform Act") was signed into law by President Trump. The Tax Reform Act significantly revised the U.S. corporate income tax regime by, among other things, lowering the U.S. corporate tax rate from 35% to 21% effective January 1, 2018. Under ASC 740, the tax effects of changes in tax laws must be recognized in the period in which the law was enacted. ASC 740 also requires deferred tax assets and liabilities to be measured at the enacted tax rate expected to apply when temporary differences are to be realized or settled. The Company re-measured its deferred tax assets and liabilities at the 21% federal corporate tax rate. The remeasurement resulted in no change in the Company’s recorded tax provision, as the remeasurement of the company's deferred tax assets and liabilities resulted in a reduction of approximately $5,843,000 which was fully offset by a change in the Company's valuation allowance.

 

We have net operating loss carry-forwards for federal income tax purposes of $38,690,000 as of December 31, 2017. Included in these numbers are loss carry-forwards that were obtained through the acquisition of BioSeq, Inc. and are subject to Section 382 NOL limitations. These net operating loss carry-forwards expire at various dates from 2018 through 2038.

 

We have net operating loss carry-forwards for state income tax purposes of approximately $31,735,000 at December 31, 2017. These net operating loss carry-forwards expire at various dates from 2030 through 2038.

 

We have research and development tax credit carry-forwards for federal income tax purposes of approximately $1,089,000 as of December 31, 2017 and research and development tax credit carry-forwards for state income tax purposes of approximately $232,000 as of December 31, 2017. The federal credit carry-forwards expire at various dates from 2018 through 2038. The state credit carry-forwards expire at various dates from 2023 through 2033.

 

In addition, we have federal alternative minimum tax credit carry-forwards for federal income tax purposes of approximately $217,000 as of December 31, 2017. These credits do not expire.

 

Our effective income tax (benefit) provision rate was different than the statutory federal income tax (benefit) provision rate as follows for the years ended December 31:

 

    2017     2016  
Federal tax provision rate     35 %     34 %
Permanent differences     (0 )%     24 %
State tax expense     0 %     0 %
Refundable AMT and R&D tax credit     0 %     0 %
Net operating loss carry back     0 %     0 %
Valuation allowance     (35 )%     (58 )%
Effective income tax provision     0 %     0 %